CN106852939A - Treat lactic bacteria composition of vaginitis and preparation method thereof - Google Patents
Treat lactic bacteria composition of vaginitis and preparation method thereof Download PDFInfo
- Publication number
- CN106852939A CN106852939A CN201610980274.0A CN201610980274A CN106852939A CN 106852939 A CN106852939 A CN 106852939A CN 201610980274 A CN201610980274 A CN 201610980274A CN 106852939 A CN106852939 A CN 106852939A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- cuf
- bacterial strains
- lactic
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of lactic bacteria composition for treating vaginitis, including lactic acid bacteria combination core, the lactic acid bacteria combination core is wrapped with coated layer；The coated layer includes the composition of parts by weight：Oligoisomaltose 30~50, protein substance 30~50, Cranberry fruit powder 5~10, nitrocellulose 5~10；The lactic acid bacteria combination core is made up of the bacterial strain of following parts by weight：Lactobacillus salivarius 30~40, lactobacillus reuteri 20~30, Lactobacillus rhamnosus 10~20, lactobacterium acidophilus 10~20.The invention also discloses its preparation method.The present invention has the advantages that significantly to treat vaginitis and without any side effects.
Description
Technical field
The present invention relates to probiotics, with significantly treatment vaginitis and without any side effects controlled more particularly, to a kind of
Treat lactic bacteria composition of vaginitis and preparation method thereof.
Background technology
Vaginitis is colpitis.Intrusion of the characteristics of normal healthy women vagina is due to anatomical tissue to pathogen has certainly
Right defense function.Such as the closure of introitus, vagina front and rear wall is close to, hyperplasia of the vaginal epithelial cell under the influence of estrogen and
Cells of superficial layer angling, vagina acid-base degree keeps balance, is suppressed the breeding of the pathogen of adaptation alkalescence, and neck tube mucus is in
Alkalescence, when the natural defense function of vagina is destroyed, pathogen is easy to invade, and can cause colpitis.The hair of vaginitis
Existence is in many reasons, but main cause is that flora imbalance causes.It is normal to parasitize healthy women vaginal flora, lactobacillus
Dominance, Lactobacillus vaginalis play key effect to maintaining vagina normal flora.The glycogen of vagina epithelium through lactobacillus effect
Lactic acid is decomposed into, makes vagina locally in weakly acidic condition.Following situations are possible to influence the balance of vaginal ecosystem：1. property swashs
Element：Such as estrogen level reduction before and after the menstrual period, intravaginal pH is caused to rise the growth for being conducive to anaerobic bacteria.2. some spermicidals are sub
Contraceptive jelly to the toxic effect of lactobacillus.3. medicine：Perhaps lactobacillus can be killed or suppressed to multi-medicament such as broad-spectrum antibiotic
And influence the environment of intravaginal.4. infect；Such as the unrest of women's property, STD etc. is infected, may interfere with the original flora of intravaginal and cause to lose
Adjust.At present, use doctor trained in Western medicine antibiotic therapy, but effect not to feel quite pleased hospital, easily recurrence, very big pain is brought to patient more
It is bitter.Therefore, a kind of good effect is developed, recurrence is difficult and the low treatment method of toxic and side effect is prior art skill urgently to be resolved hurrily
Art problem.
The content of the invention
It is a kind of with significantly treatment vaginitis and without any present invention aim at providing to overcome the shortcoming of prior art
Lactic bacteria composition for the treatment of vaginitis of toxic and side effect and preparation method thereof.
The present invention is by following technical measures realization, a kind of lactic bacteria composition for treating vaginitis, including lactic acid bacteria
Combination core, the lactic acid bacteria combination core is wrapped with coated layer；The coated layer includes the composition of parts by weight：Oligomeric different malt
Sugar 30~50, protein substance 30~50, Cranberry fruit powder 5~10, nitrocellulose 5~10；The lactic acid bacteria combines core by such as
The bacterial strain composition of lower parts by weight：Lactobacillus salivarius 30~40, lactobacillus reuteri 20~30, Lactobacillus rhamnosus 10~20,
Lactobacterium acidophilus 10~20.
Used as a kind of preferred embodiment, the content of Lactobacillus salivarius is 10 in the lactic bacteria composition7~109Cuf/g, sieve
The content of Yi Shi lactobacillus is 106~108Cuf/g, the content of Lactobacillus rhamnosus are 106~107Cuf/g, lactobacterium acidophilus
Content is 106~107cuf/g。
As a kind of preferred embodiment, Lactobacillus salivarius, lactobacillus reuteri, rhamnose breast bar in the lactic acid bacteria combination core
Bacterium and lactobacterium acidophilus are resistant to 0.3% Pig cholate and acyclic acidic that pH is 2.5 respectively through resistance to Pig cholate, acidproof screening
Border.
Used as a kind of preferred embodiment, the lactobacillus reuteri is GL-104 bacterial strains, and the Lactobacillus salivarius is AP-32 bacterium
Strain, deposit number CCTCC NO：M2011127；The lactobacillus reuteri is TE-33 bacterial strains, deposit number CCTCC NO：
M2011126；The Lactobacillus rhamnosus is CT-53 bacterial strains, deposit number CCTCC NO：M2011129；The lactobacillus acidophilus
It is F-1 bacterial strains, deposit number CCTCC NO：M2011124.
Used as a kind of preferred embodiment, the protein substance is casein and lactoferrin layer, wherein casein and newborn iron egg
White weight ratio is 1-5：1-5.
Also a kind of preparation method of the lactic bacteria composition for treating vaginitis of the present invention, comprises the following steps：
(1) by Lactobacillus salivarius, lactobacillus reuteri, Lactobacillus rhamnosus, lactobacterium acidophilus respectively with 1ml/100ml's
Inoculum concentration is seeded in culture medium, at 35 DEG C~45 DEG C, cultivates 12~24h, the lactobacillus strain for being activated；
(2) the four kinds of strains that will be activated are with parts by weight：Lactobacillus salivarius 30~40, lactobacillus reuteri 20~30, mouse
After Lee's sugar lactobacillus 10~20, lactobacterium acidophilus 10~20 mix, then mixed bacteria is seeded to the inoculum concentration of 1ml/100ml
In nutrient solution, at 35 DEG C~45 DEG C, after 10~12h of culture, centrifuging and taking precipitation, after being incubated 6~10h at 4 DEG C~10 DEG C,
Matter, obtains combination strain；
(3) by parts by weight：Oligoisomaltose 30~50, protein substance 30~50, Cranberry fruit powder 5~10, nitre
Acid cellulose 5~10 is added water and is sufficiently mixed into coating buffer, and combination strain addition coating buffer is mixed evenly；
(4) liquid that will be mixed evenly solidifies in being added drop-wise to calcium chloride solution, and vacuum freeze-drying 12h obtains lactic acid bacteria after filtering
Composition.
Used as a kind of preferred embodiment, the content of Lactobacillus salivarius is 10 in the lactic bacteria composition7~109Cuf/g, sieve
The content of Yi Shi lactobacillus is 106~108Cuf/g, the content of Lactobacillus rhamnosus are 106~107Cuf/g, lactobacterium acidophilus
Content is 106~107cuf/g。
As a kind of preferred embodiment, the Lactobacillus salivarius, lactobacillus reuteri, Lactobacillus rhamnosus and lactobacterium acidophilus
Before activation respectively through resistance to Pig cholate, acidproof screening, 0.3% Pig cholate and sour environment that pH is 2.5 are resistant to.
Used as a kind of preferred embodiment, the Lactobacillus salivarius is AP-32 bacterial strains, deposit number CCTCC NO：M2011127；
The lactobacillus reuteri is TE-33 bacterial strains, deposit number CCTCC NO：M2011126；The Lactobacillus rhamnosus is CT-53
Bacterial strain, deposit number CCTCC NO：M2011129；The lactobacillus acidophilus is F-1 bacterial strains, deposit number CCTCC NO：
M2011124。
Used as a kind of preferred embodiment, the protein substance is casein and lactoferrin layer, wherein casein and newborn iron egg
White weight ratio is 1-5：1-5.
The present invention has the effect of significantly treatment vaginitis, and because being prebiotic becteriums product, does not have any poison to human body
Side effect.
Specific embodiment
The present invention is described in further detail with reference to embodiment.
Embodiment 1
(1) actication of culture
Filter out the Lactobacillus salivarius AP-32 bacterial strains of resistance to 0.3% Pig cholate, the sour environment that resistance to PH is 2.5, deposit number
CCTCC NO：M2011127；Lactobacillus reuteri TE-33 bacterial strains, deposit number CCTCC NO：M2011126；Rhamnose breast bar
Bacterium CT-53 bacterial strains, deposit number CCTCC NO：M2011129；Lactobacillus acidophilus F-1 bacterial strains, deposit number CCTCC NO：
M2011124.The four kinds of bacterium that will be filtered out are seeded in MRS culture mediums with the inoculum concentration of 1ml/100ml respectively, at 45 DEG C, training
Support 12h, the lactobacillus strain for being activated；
Wherein, the formula of MRS culture mediums is：10g peptones, 8g beef extract powders, 20g Portugals are added in 1000mL distilled water
Grape sugar, 4g yeast extracts, the water manganese sulfates of 0.05g tetra-, 1mL Tween 80s, 2g dipotassium hydrogen phosphates, 5g sodium acetates, 0.2g magnesium sulfate, 2g
Dibasic ammonium citrate；
(2) combination strain is prepared
The four kinds of strains that will be activated are with parts by weight：Lactobacillus salivarius 30g, lactobacillus reuteri 20g, Lactobacillus rhamnosus
After 10g, lactobacterium acidophilus 10g mixing, then mixed bacteria is seeded in nutrient solution with the inoculum concentration of 1ml/100ml, at 45 DEG C
Under, after culture 10h, with 6000r/min, at 5 DEG C, centrifugation 15min, taking precipitate, after being incubated 6h at 4 DEG C, homogeneous is obtained
Combination strain；
(3) coating combination strain is prepared
By following weight：Oligoisomaltose 30g, casein 15g, lactoferrin 15g, nitrocellulose 5g add water
1000ml is sufficiently mixed into coating buffer, and combination strain addition coating buffer is mixed evenly；
(4) lactic bacteria composition is prepared
The liquid that will be mixed evenly solidifies in being added drop-wise to calcium chloride solution, and vacuum freeze-drying 12h obtains lactic acid bacteria group after filtering
Compound.The content of Lactobacillus salivarius is 10 in lactic bacteria composition7~109Cuf/g, the content of lactobacillus reuteri are 106~
108Cuf/g, the content of Lactobacillus rhamnosus are 106~107Cuf/g, the content of lactobacterium acidophilus are 106~107cuf/g。
Embodiment 2
Filter out the Lactobacillus salivarius AP-32 bacterial strains of resistance to 0.3% Pig cholate, the sour environment that resistance to PH is 2.5, deposit number
CCTCC NO：M2011127；Lactobacillus reuteri TE-33 bacterial strains, deposit number CCTCC NO：M2011126；Rhamnose breast bar
Bacterium CT-53 bacterial strains, deposit number CCTCC NO：M2011129；Lactobacillus acidophilus F-1 bacterial strains, deposit number CCTCC NO：
M2011124.The four kinds of bacterium that will be filtered out are seeded in MRS culture mediums with the inoculum concentration of 1ml/100ml respectively, at 35 DEG C, training
Support 24h, the lactobacillus strain for being activated；
Wherein, the formula of MRS culture mediums is：10g peptones, 8g beef extract powders, 20g Portugals are added in 1000mL distilled water
Grape sugar, 5g yeast extracts, the water manganese sulfates of 0.06g tetra-, 1mL Tween 80s, 2g dipotassium hydrogen phosphates, 5g sodium acetates, 0.2g magnesium sulfate, 2g
Dibasic ammonium citrate；
(2) combination strain is prepared
The four kinds of strains that will be activated are with parts by weight：Lactobacillus salivarius 40g, lactobacillus reuteri 30g, Lactobacillus rhamnosus
After 20g, lactobacterium acidophilus 20g mixing, then mixed bacteria is seeded in nutrient solution with the inoculum concentration of 1ml/100ml, at 35 DEG C
Under, after culture 12h, with 4500r/min, at 10 DEG C, centrifugation 20min, taking precipitate, after being incubated 10h at 10 DEG C, homogeneous,
Obtain combination strain；
(3) coating combination strain is prepared
By following weight：Oligoisomaltose 50g, casein 35g, lactoferrin 35g, nitrocellulose 10g add water
1000ml is sufficiently mixed into coating buffer, and combination strain addition coating buffer is mixed evenly；
(4) lactic bacteria composition is prepared
The liquid that will be mixed evenly solidifies in being added drop-wise to calcium chloride solution, and vacuum freeze-drying 12h obtains lactic acid bacteria group after filtering
Compound.The content of Lactobacillus salivarius is 10 in lactic bacteria composition7~109Cuf/g, the content of lactobacillus reuteri are 106~
108Cuf/g, the content of Lactobacillus rhamnosus are 106~107Cuf/g, the content of lactobacterium acidophilus are 106~107cuf/g。
Embodiment 3
Filter out the Lactobacillus salivarius AP-32 bacterial strains of resistance to 0.3% Pig cholate, the sour environment that resistance to PH is 2.5, deposit number
CCTCC NO：M2011127；Lactobacillus reuteri TE-33 bacterial strains, deposit number CCTCC NO：M2011126；Rhamnose breast bar
Bacterium CT-53 bacterial strains, deposit number CCTCC NO：M2011129；Lactobacillus acidophilus F-1 bacterial strains, deposit number CCTCC NO：
M2011124.The four kinds of bacterium that will be filtered out are seeded in MRS culture mediums with the inoculum concentration of 1ml/100ml respectively, at 42 DEG C, training
Support 13h, the lactobacillus strain for being activated；
Wherein, the formula of MRS culture mediums is：10g peptones, 8g beef extract powders, 20g Portugals are added in 1000mL distilled water
Grape sugar, 4g yeast extracts, the water manganese sulfates of 0.05g tetra-, 1mL Tween 80s, 2g dipotassium hydrogen phosphates, 5g sodium acetates, 0.2g magnesium sulfate, 2g
Dibasic ammonium citrate；
(2) combination strain is prepared
The four kinds of strains that will be activated are with parts by weight：Lactobacillus salivarius 35g, lactobacillus reuteri 23g, Lactobacillus rhamnosus
After 15g, lactobacterium acidophilus 15g mixing, then mixed bacteria is seeded in nutrient solution with the inoculum concentration of 1ml/100ml, at 42 DEG C
Under, after culture 11h, with 7000r/min, at 5 DEG C, centrifugation 10min, taking precipitate, after being incubated 10h at 4 DEG C, homogeneous is obtained
To combination strain；
(3) coating combination strain is prepared
By parts by weight：Oligoisomaltose 35g, casein 20g, lactoferrin 20g, nitrocellulose 6g add water
1000ml is sufficiently mixed into coating buffer, and combination strain addition coating buffer is mixed evenly；
(4) lactic bacteria composition freeze-dried powder is prepared
The liquid that will be mixed evenly solidifies in being added drop-wise to calcium chloride solution, and vacuum freeze-drying 12h obtains lactic acid bacteria group after filtering
Compound freeze-dried powder.The content of Lactobacillus salivarius is 10 in lactic bacteria composition freeze-dried powder7~109Cuf/g, lactobacillus reuteri
Content be 106~108Cuf/g, the content of Lactobacillus rhamnosus are 106~107Cuf/g, the content of lactobacterium acidophilus are 106~
107cuf/g。
It is used to further illustrate the present invention below by clinical test.
1st, clinical observation
Using lactic bacteria composition freeze-dried powder of the present invention (being prepared according to the method for embodiment 1) treatment patient totally 240, pass through
Gynecologial examination is made a definite diagnosis, 20~48 years old its age, average 33 years old.It is randomly divided into two groups, control group 120, treatment group 120.
2nd, medicament selection
Control group using oral medicine woman inflammation capsule (Divine Land pharmacy), 0.4g/, one time 3,2 times a day, continuously take 30
My god；
Treatment group anthology invention lactic bacteria composition freeze-dried powder (is prepared) according to the method for embodiment 1, course for the treatment of (30 days
The course for the treatment of), 1.5g/ bags, two times a day, 2 bags every time, boiling water is taken after mixing it with water.
3rd, diagnostic criteria
Vaginal fluid increases, pruritus vulvue, cusalgia, can be with frequent micturition, odynuria and intercourse pain；Gynecologial examination finds vagina
Secretion increases, vagina mucosa it is congested or it is visible be dispersed in bleeding spot, posterior fornix of vagina has volume leukorrhea, in lark or yellowish green
Color purulent secretion, show bubble or white stiff curdled milk or bean dregs sample sometimes, the visible oedema of vulva, scratch, pattern erythema；
Vaginal fluid laboratory examination finds gemma and the mycelia of trichomonad or candidiasis.
4th, efficacy assessment standard
Cure：After treatment end, clinical symptoms are wholly absent；
Effectively：After treatment end, clinical symptoms partial disappearance, the state of an illness is alleviated substantially；
It is invalid：After treatment end, clinical symptoms are not taken on a new look substantially, and disease amelioration is not obvious.
Specific treatment results see the table below：
| Group | Treatment number | Cure | Effectively | It is invalid | Total effective rate |
| Control group | 120 | 32 | 39 | 49 | 59.2% |
| Treatment group | 120 | 75 | 42 | 3 | 97.5% |
Conclusion：The cure rate for the treatment of group is 45%, and effective percentage is 90%, significantly larger than control group.
Model case
Case 1：Lee so-and-so, 50 years old.Main suit：Pruritus vulvue more than 1 year, with frequent micturition, odynuria and intercourse pain, takes Western medicine
Half a year is more, and recurrence is twice.Check and find, vaginal fluid increases, posterior fornix of vagina has volume leukorrhea, vaginal fluid chemical examination inspection
Look into discovery trichomonad.Take lactic bacteria composition freeze-dried powder of the present invention (being prepared according to the method for embodiment 1), a course for the treatment of, one day two
Secondary, 2 bags every time, boiling water is taken after mixing it with water, and after continuous 10 days, symptom disappears, and is continuing with consolidating within 20 days stabilization therapeutic effect；Follow-up 1 year
No relapse.
Case 2：Wang, 22 years old, main suit：Pruritus vulvue, cusalgia, vaginal fluid increase, after gynecologial examination finds vagina
Arched roof has a large amount of stiff curdled milk sample leukorrhea, and vaginal fluid checks the mycelia of visible candidiasis, is diagnosed as and examines mycotic the moon
Road is scorching.Take lactic bacteria composition freeze-dried powder of the present invention (according to the method for embodiment 1 prepare), a course for the treatment of, two times a day, every time
2 bags, boiling water is taken after mixing it with water, and after continuous 15 days, symptom disappears, and is continuing with consolidating within 15 days stabilization therapeutic effect；Follow-up half a year has no multiple
Hair.
Above is lactic bacteria composition of vaginitis and preparation method thereof is treated to the present invention being set forth, it is used to help
Understand the present invention, but embodiments of the present invention and be not restricted to the described embodiments, it is any without departing from institute under the principle of the invention
The change of work, modification, replacement, combination, simplify, should be equivalent substitute mode, be included in protection scope of the present invention it
It is interior.
Claims (10)
1. a kind of lactic bacteria composition for treating vaginitis, it is characterised in that：Core, the lactic acid bacteria combination are combined including lactic acid bacteria
Core is wrapped with coated layer；The coated layer includes the composition of parts by weight：Oligoisomaltose 30~50, protein substance 30~
50th, Cranberry fruit powder 5~10, nitrocellulose 5~10；The lactic acid bacteria combination core is made up of the bacterial strain of following parts by weight：
Lactobacillus salivarius 30~40, lactobacillus reuteri 20~30, Lactobacillus rhamnosus 10~20, lactobacterium acidophilus 10~20.
2. lactic bacteria composition according to claim 1, it is characterised in that：Lactobacillus salivarius in the lactic bacteria composition
Content be 107~109Cuf/g, the content of lactobacillus reuteri are 106~108Cuf/g, the content of Lactobacillus rhamnosus are 106
~107Cuf/g, the content of lactobacterium acidophilus are 106~107cuf/g。
3. lactic bacteria composition according to claim 1, it is characterised in that：Saliva breast bar in the lactic acid bacteria combination core
Bacterium, lactobacillus reuteri, Lactobacillus rhamnosus and lactobacterium acidophilus are resistant to 0.3% respectively through resistance to Pig cholate, acidproof screening
Pig cholate and sour environment that pH is 2.5.
4. lactic bacteria composition according to claim 1, it is characterised in that：The Lactobacillus salivarius is AP-32 bacterial strains, is protected
Hide numbering CCTCC NO：M2011127；The lactobacillus reuteri is TE-33 bacterial strains, deposit number CCTCC NO：
M2011126；The Lactobacillus rhamnosus is CT-53 bacterial strains, deposit number CCTCC NO：M2011129；The lactobacillus acidophilus
It is F-1 bacterial strains, deposit number CCTCC NO：M2011124.
5. lactic bacteria composition according to claim 1, it is characterised in that：The protein substance is casein and newborn iron egg
The weight ratio of white, wherein casein and lactoferrin is 1-5：1-5.
6. a kind of preparation method of the lactic bacteria composition for treating vaginitis, it is characterised in that comprise the following steps：
(1) by Lactobacillus salivarius, lactobacillus reuteri, Lactobacillus rhamnosus, lactobacterium acidophilus respectively with the inoculation of 1ml/100ml
Amount is seeded in culture medium, at 35 DEG C~45 DEG C, cultivates 12~24h, the lactobacillus strain for being activated；
(2) the four kinds of strains that will be activated are with parts by weight：Lactobacillus salivarius 30~40, lactobacillus reuteri 20~30, rhamnose
After lactobacillus 10~20, lactobacterium acidophilus 10~20 mix, then mixed bacteria is seeded to culture with the inoculum concentration of 1ml/100ml
In liquid, at 35 DEG C~45 DEG C, after 10~12h of culture, centrifuging and taking precipitation, after being incubated 6~10h at 4 DEG C~10 DEG C, homogeneous,
Obtain combination strain；
(3) by parts by weight：Oligoisomaltose 30~50, protein substance 30~50, Cranberry fruit powder 5~10, nitric acid are fine
Dimension element 5~10 is added water and is sufficiently mixed into coating buffer, and combination strain addition coating buffer is mixed evenly；
(4) liquid that will be mixed evenly solidifies in being added drop-wise to calcium chloride solution, and vacuum freeze-drying 12h obtains lactic acid bacteria combination after filtering
Thing.
7. preparation method according to claim 6, it is characterised in that：Lactobacillus salivarius contains in the lactic bacteria composition
Measure is 107~109Cuf/g, the content of lactobacillus reuteri are 106~108Cuf/g, the content of Lactobacillus rhamnosus are 106~
107Cuf/g, the content of lactobacterium acidophilus are 106~107cuf/g。
8. preparation method according to claim 6, it is characterised in that：The Lactobacillus salivarius, lactobacillus reuteri, sandlwood
Sugared lactobacillus and lactobacterium acidophilus respectively through resistance to Pig cholate, acidproof screening, are resistant to 0.3% Pig cholate and pH before activation
It is 2.5 sour environment.
9. preparation method according to claim 6, it is characterised in that：The Lactobacillus salivarius is AP-32 bacterial strains, and preservation is compiled
Number CCTCC NO：M2011127；The lactobacillus reuteri is TE-33 bacterial strains, deposit number CCTCC NO：M2011126；Institute
Lactobacillus rhamnosus is stated for CT-53 bacterial strains, deposit number CCTCC NO：M2011129；The lactobacillus acidophilus is F-1 bacterial strains,
Deposit number CCTCC NO：M2011124.
10. preparation method according to claim 6, it is characterised in that：The protein substance is casein and lactoferrin
Layer, wherein the weight ratio of casein and lactoferrin are 1-5：1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610980274.0A CN106852939A (en) | 2016-11-08 | 2016-11-08 | Treat lactic bacteria composition of vaginitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610980274.0A CN106852939A (en) | 2016-11-08 | 2016-11-08 | Treat lactic bacteria composition of vaginitis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106852939A true CN106852939A (en) | 2017-06-16 |
Family
ID=59125684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610980274.0A Pending CN106852939A (en) | 2016-11-08 | 2016-11-08 | Treat lactic bacteria composition of vaginitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106852939A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107362292A (en) * | 2017-07-19 | 2017-11-21 | 颐和益生（北京）科技有限公司 | It is a kind of that there is the composition for improving female genitourinary system inflammation, preparation method and application |
| CN108310364A (en) * | 2018-04-26 | 2018-07-24 | 霍尔果斯汉智医药科技有限公司 | A kind of amphotericin B vaginal expansion plug and preparation method thereof |
| CN108324932A (en) * | 2018-04-26 | 2018-07-27 | 霍尔果斯汉智医药科技有限公司 | A kind of lactoferrin vaginal expansion plug and preparation method thereof |
| CN110373342A (en) * | 2018-04-13 | 2019-10-25 | 深圳市华大农业应用研究院 | Lactobacillus reuteri and application thereof |
| CN111150059A (en) * | 2020-01-19 | 2020-05-15 | 西倍健生物科技(深圳)有限公司 | Special probiotic bacterium composition for women and application thereof |
| US20200390119A1 (en) * | 2019-06-14 | 2020-12-17 | Glac Biotech Co., Ltd. | Food composition and pharmaceutical composition with strains of lactic acid bacteria and method for modulating blood glucose |
| CN112806576A (en) * | 2019-10-29 | 2021-05-18 | 锦乔生物科技有限公司 | Composition for inhibiting pathogenic bacteria of vaginitis, vagina cleaning composition and application thereof |
| CN113287753A (en) * | 2021-05-24 | 2021-08-24 | 国珍健康科技（北京）有限公司 | Probiotic composition for improving female vagina inflammation |
| CN114452379A (en) * | 2020-11-10 | 2022-05-10 | 西安正浩生物制药有限公司 | Probiotic composition containing active lactic acid and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727531A (en) * | 2012-07-23 | 2012-10-17 | 郑州金森生物科技工程有限公司 | Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis |
| CN102835657A (en) * | 2011-06-20 | 2012-12-26 | 丰华生物科技股份有限公司 | Lactic acid bacteria-containing food composition and pharmaceutical composition used for inhibiting inflammatory response and resisting vaginitis |
| CN104543611A (en) * | 2015-01-09 | 2015-04-29 | 东北农业大学 | Application of whey protein and reducing oligosaccharide Maillard product to microcapsule wall materials and embedded probiotics |
| CN104719769A (en) * | 2015-04-13 | 2015-06-24 | 山东省鲁洲食品集团有限公司 | Processing method of healthcare type instant maize germ milk powder |
| CN104783028A (en) * | 2014-01-21 | 2015-07-22 | 四川亿生元科技有限公司 | A probiotic and a processing method thereof |
| CN105661245A (en) * | 2016-01-29 | 2016-06-15 | 江苏微康生物科技有限公司 | Probiotic type fruit and vegetable enzyme solid drink |
-
2016
- 2016-11-08 CN CN201610980274.0A patent/CN106852939A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102835657A (en) * | 2011-06-20 | 2012-12-26 | 丰华生物科技股份有限公司 | Lactic acid bacteria-containing food composition and pharmaceutical composition used for inhibiting inflammatory response and resisting vaginitis |
| CN102727531A (en) * | 2012-07-23 | 2012-10-17 | 郑州金森生物科技工程有限公司 | Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis |
| CN104783028A (en) * | 2014-01-21 | 2015-07-22 | 四川亿生元科技有限公司 | A probiotic and a processing method thereof |
| CN104543611A (en) * | 2015-01-09 | 2015-04-29 | 东北农业大学 | Application of whey protein and reducing oligosaccharide Maillard product to microcapsule wall materials and embedded probiotics |
| CN104719769A (en) * | 2015-04-13 | 2015-06-24 | 山东省鲁洲食品集团有限公司 | Processing method of healthcare type instant maize germ milk powder |
| CN105661245A (en) * | 2016-01-29 | 2016-06-15 | 江苏微康生物科技有限公司 | Probiotic type fruit and vegetable enzyme solid drink |
Non-Patent Citations (1)
| Title |
|---|
| HUMMELEN,R.等: "Lactobacillus rhamnosus GR‐1 and L. reuteri RC‐14 to prevent or cure bacterial vaginosis among women with HIV", 《INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS》 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107362292A (en) * | 2017-07-19 | 2017-11-21 | 颐和益生（北京）科技有限公司 | It is a kind of that there is the composition for improving female genitourinary system inflammation, preparation method and application |
| CN110373342A (en) * | 2018-04-13 | 2019-10-25 | 深圳市华大农业应用研究院 | Lactobacillus reuteri and application thereof |
| CN110373342B (en) * | 2018-04-13 | 2022-11-01 | 深圳华大基因农业控股有限公司 | Lactobacillus reuteri and uses thereof |
| CN108310364A (en) * | 2018-04-26 | 2018-07-24 | 霍尔果斯汉智医药科技有限公司 | A kind of amphotericin B vaginal expansion plug and preparation method thereof |
| CN108324932A (en) * | 2018-04-26 | 2018-07-27 | 霍尔果斯汉智医药科技有限公司 | A kind of lactoferrin vaginal expansion plug and preparation method thereof |
| US20200390119A1 (en) * | 2019-06-14 | 2020-12-17 | Glac Biotech Co., Ltd. | Food composition and pharmaceutical composition with strains of lactic acid bacteria and method for modulating blood glucose |
| US11612171B2 (en) * | 2019-06-14 | 2023-03-28 | Glac Biotech Co., Ltd. | Food composition and pharmaceutical composition with strains of lactic acid bacteria and method for modulating blood glucose |
| CN112806576A (en) * | 2019-10-29 | 2021-05-18 | 锦乔生物科技有限公司 | Composition for inhibiting pathogenic bacteria of vaginitis, vagina cleaning composition and application thereof |
| CN112806576B (en) * | 2019-10-29 | 2024-04-05 | 锦乔生物科技有限公司 | Composition for inhibiting colpitis pathogenic bacteria, vagina cleaning composition and application thereof |
| CN111150059A (en) * | 2020-01-19 | 2020-05-15 | 西倍健生物科技(深圳)有限公司 | Special probiotic bacterium composition for women and application thereof |
| CN114452379A (en) * | 2020-11-10 | 2022-05-10 | 西安正浩生物制药有限公司 | Probiotic composition containing active lactic acid and preparation method thereof |
| CN113287753A (en) * | 2021-05-24 | 2021-08-24 | 国珍健康科技（北京）有限公司 | Probiotic composition for improving female vagina inflammation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106852939A (en) | Treat lactic bacteria composition of vaginitis and preparation method thereof | |
| CN103719609B (en) | Feed for lactating sows and preparation method thereof | |
| CN103829092A (en) | Traditional Chinese medicinal composition and feed for treating escherichia coli diarrhea of piglets | |
| CN107050062A (en) | Treat lactic bacteria composition of constipation and preparation method thereof | |
| CN109674826A (en) | A kind of probiotic composition for nursing female reproductive system | |
| CN107050063A (en) | Treat lactic bacteria composition of allergic constitution and preparation method thereof | |
| CN102613413A (en) | Feed and traditional Chinese medicine for treating white scour of piglets and preparation method as well as applications | |
| CN106957811B (en) | Format lactobacillus and Chinese medicine compound prescription with bacteriostasis and its application in treatment gynaecological imflammation | |
| CN107648660A (en) | A kind of antiphlogistic antibacterial type tapon and preparation method thereof | |
| CN114921389A (en) | Probiotic composition with female intestinal private part nursing and mammary gland anti-inflammatory effects and application thereof | |
| CN101797269B (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| CN110101715A (en) | Soil preparation and the preparation method and application thereof with prevention and treatment neuroendocrine disorders related disease | |
| CN106309506A (en) | Probiotic composition with menstruation regulating function and application thereof | |
| CN103830616B (en) | A traditional Chinese medicine for treating swine fever and a preparation method thereof | |
| CN113274414A (en) | Probiotics preparation for repairing and maintaining vaginal microecological balance | |
| CN106974278A (en) | A kind of prostate nutrient powder and its preparation method and application | |
| CN106619742A (en) | Lactic acid bacteria composition used for treating diabetes, and preparation method thereof | |
| CN102716408B (en) | Application of tsaoko amomum fruit to preparation of medicament for treating vaginitis | |
| CN109897795A (en) | A kind of microbial bacterial agent and its application on anti-treat constipation | |
| CN104547770A (en) | Fermented traditional Chinese medicament for promoting growth of livestock and poultry and preparation method for fermented traditional Chinese medicament | |
| CN107586746A (en) | One plant of lactic acid bacteria with preventing and treating mastitis for milk cows effect and its application | |
| CN106943494A (en) | Vagina cleaning bacteriostasis washing lotion and preparation method thereof | |
| CN106361905A (en) | Compound Chinese herbal microecological preparation with efficacies of supporting right and resolving toxins for beasts and birds and preparation method of compound Chinese herbal microecological preparation | |
| CN106265684A (en) | The application of Lupenyl acetate | |
| CN110251603A (en) | Prevent and treat the Chinese medicine composition and preparation method thereof of sheep Eaton agent pneumonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170616 |
|
| RJ01 | Rejection of invention patent application after publication |